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Abstract
 
T helper type 1 (Th1)-type CD4
 
 
 
 antitumor T cell help appears critical to the induction and
maintenance of antitumor cytotoxic T lymphocyte (CTL) responses in vivo
 
.
 
 In contrast, Th2- or
Th3/Tr-type CD4
 
 
 
 T cell responses may subvert Th1-type cell-mediated immunity, providing
a microenvironment conducive to disease progression. We have recently identified helper T cell
epitopes derived from the MAGE-6 gene product; a tumor-associated antigen expressed by most
melanomas and renal cell carcinomas. In this study, we have assessed whether peripheral blood
CD4
 
 
 
 T cells from human histocompatibility leukocyte antigens (HLA)-DR
 
 
 
1
 
*
 
0401
 
 
 
 patients
are Th1- or Th2-biased to MAGE-6 epitopes using interferon (IFN)-
 
 
 
 and interleukin (IL)-5
enzyme-linked immunospot assays, respectively. Strikingly, the vast majority of patients with ac-
tive disease were highly-skewed toward Th2-type responses against MAGE-6–derived epitopes,
regardless of their stage (stage I versus IV) of disease, but retained Th1-type responses against Ep-
stein-Barr virus– or influenza-derived epitopes. In marked contrast, normal donors and cancer
patients with no current evidence of disease tended to exhibit either mixed Th1/Th2 or strongly
Th1-polarized responses to MAGE-6 peptides, respectively. CD4
 
 
 
 T cell secretion of IL-10 and
transforming growth factor (TGF)-
 
 
 
1 against MAGE-6 peptides was not observed, suggesting
that specific Th3/Tr-type CD4
 
 
 
 subsets were not common events in these patients. Our data
suggest that immunotherapeutic approaches will likely have to overcome or complement sys-
temic Th2-dominated, tumor-reactive CD4
 
 
 
 T cell responses to provide optimal clinical benefit.
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Introduction
 
Although renal cell carcinoma (RCC)
 
*
 
 and melanoma are
considered among the most responsive cancers to immuno-
therapy, the vast majority of recent immunotherapeutic
approaches have focused solely on the induction of CD8
 
 
 
antitumor T cells in vivo as a surrogate of clinical benefit
(1–3). It appears clear that the ability to promote effector
CD8
 
 
 
 T cells reactive against tumor antigens is a necessary,
but not sufficient, event in objective clinical responses (4).
CD4
 
 
 
 T cells can also recognize tumor antigen-derived
peptides, either directly (as some RCCs and melanomas
express MHC class II molecules in situ; references 5 and 6)
or via cross-presentation mechanisms by host antigen-pre-
senting cells, such as dendritic cells (DCs; references 7 and
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8). Th1-type CD4
 
 
 
 T cells secreting IFN-
 
 
 
 appear crucial
to the optimal generation and durability of specific CTL in
vivo and may also serve to recruit these effector cells into
the tumor microenvironment via delayed-type hypersensi-
tivity responses (8). Hence, the lack of effectively promot-
ing specific Th1-type CD4
 
 
 
 T cell generation, mainte-
nance, and direction for antitumor CD8
 
 
 
 T cells may
represent a significant limitation in current vaccine trials.
Tumor-induced deviation of CD4
 
 
 
 T cell responses in
progressive disease and the role of Th1- and Th2-type
CD4
 
 
 
 effector cells have been evaluated in a limited num-
ber of murine models (9–19). Studies using the B16 mela-
noma model have documented a gradual shift of initial
Th0-, mixed Th1-/Th2-type CD4
 
 
 
 T cell response to
Th2/Tr-type dominated responses by 14–20 d of progres-
sive tumor growth (13, 17–19). Injection of neutralizing
anti–IL-4, -IL-10, or -TGF-
 
 
 
1 antibodies can prevent this
tumor-induced functional transition, resulting in enhanced
CD8
 
 
 
 CTL generation and protection against tumor
growth (17). Depletion of CD4
 
 
 
 T cells in late-stage pro-
gressive B16 models, where Th2/Tr-type response domi-
nate, restores CTL effector function and can result in
tumor regression and vitiligo, particularly upon adminis-
tration of rIL-12 (13). Analyses of the anti-tumor efficacy
of Th1- and Th2-type CD4
 
 
 
 T cells has also been evalu-
ated in prophylactic and adoptive transfer tumor models
(9, 12, 13, 15). In these latter cases, Th1- and Th2-type
can mediate complementary antitumor effector functions,
via contrasting mechanisms (9). Although Th2-type CD4
 
 
 
T cells can promote the recruitment of tumoricidal eo-
sinophils and macrophages into the tumor microenviron-
ment and promote acute tumor rejection (9), on a cell-
per-cell basis Th1-type T cells appear to provide a greater
therapeutic index (12, 14, 15) and only Th1-type CD4
 
 
 
T cells appear to promote durable anti-tumor CTL re-
sponses (15).
Interestingly, tumor infiltrating lymphocytes in patients
with spontaneous and therapeutically induced regressing
lesions appear to be characterized by dominant Th1-type
responses to mitogens, whereas tumor infiltrating lympho-
cytes from patients with progressor lesions have been re-
ported to exhibit functionally dominant Th2-type (IL-4,
IL-5) and/or Th3-/Tr-type (IL-10, TGF-
 
 
 
1) CD4
 
 
 
 T
cell responses (20–22). However, prior analyses of patient
bulk CD4
 
 
 
 T cell responses to mitogenic stimuli have
yielded equivocal results, with generally no clear-cut Th1-
or Th2-type bias observed (23–25). As this difference in
results may reflect the stringency with which tumor-spe-
cific CD4
 
 
 
 T cell responses were evaluated, significant re-
cent emphasis has been placed on the identification of tu-
mor antigen-derived helper T cell epitopes that may be
used to quantitate and assess tumor-specific CD4
 
 
 
 T cell
numbers and function.
Based on IFN-
 
 
 
 as a read-out cytokine or proliferation
as an endpoint, Th1-type epitopes have been identified
for the MART-1/Melan-A, gp100/pmel17, tyrosinase,
MAGE-3, and MAGE-6 (unpublished data) melanoma-asso-
ciated antigens, among others (26–28). We have recently
defined a set of helper epitopes derived from the MAGE-6
protein and have focused on these targets in the current
study, since expression of MAGE-6 (unpublished data) has
been observed in premalignant lesions in situ and at high
frequencies in primary and metastatic tumors (29–31).
Hence, CD4
 
 
 
 T cell responses to MAGE-6 epitopes may
represent early etiologic events. The bias of MAGE-6 (tu-
mor)-specific CD4
 
 
 
 T cell responses (i.e., Th1, Th2, Th3/
Tr) may impact cancer incidence in susceptible individuals,
the progression status of established MAGE-6
 
 
 
 tumors or
time to recurrence of MAGE-6
 
 
 
 disease in the adjuvant
setting. Indeed, melanoma expression of HLA-DR has
been reported to be a marker of poor prognosis (32, 33),
suggesting that the nature of CD4
 
 
 
 T cell recognition of
MHC class II–presented tumor epitopes may play a deci-
sive immunoregulatory role in situ.
This study is the first to demonstrate tumor antigen-spe-
cific Th2-type polarization of CD4
 
 
 
 T cell responses in the
peripheral blood of patients with RCC or melanoma. We
have implemented IFN-
 
 
 
 and IL-5 ELISPOT assays to as-
sess the magnitude of Th1- and Th2-type CD4
 
 
 
 T cell re-
sponses to MAGE-6 epitopes, respectively. We report that
HLA-DR
 
 
 
1
 
*
 
0401
 
 
 
 patients with active melanoma or
RCC displayed strongly polarized Th2-type reactivity to
these peptides, whereas normal donors and patients that
were disease-free following therapeutic intervention exhib-
ited either weak mixed Th1-/Th2-type or strongly-polar-
ized Th1-type responses to these same epitopes.
 
Materials and Methods
 
Cell Lines and Media.
 
The T2.DR4 (DRB1
 
*
 
0401
 
 
 
) cell line
(provided by Dr. Janice Blum, Indiana University School of
Medicine, Indianapolis, IN) was used as the peptide-presenting
cell in these studies. This cell line uniformly expresses HLA-
DR
 
*
 
0401 molecules that contain moderate-to-low affinity bind-
ing peptides derived mainly from intracellular invariant chain
(class II–associated invariant chain peptide [CLIP]) due to a ge-
netic deficiency in HLA-DM (34). T2.DR4 cells were main-
tained in RPMI-1640 supplemented with 10% heat-inactivated
FBS, 100 IU/ml penicillin, 100 
 
 
 
g/ml streptomycin, and 10 mM
L-glutamine (all reagents GIBCO BRL).
 
Peptide Selection and Synthesis.
 
The MAGE-6 (unpublished
data), influenza A matrix
 
60–73
 
 (35), malarial circumsporozoo-
ite
 
326–345
 
 (26) and EBV EBNA-1
 
519–533
 
 (36) HLA-DR4-presented
epitopes were synthesized by FMOC chemistry by the University
of Pittsburgh Cancer Institute’s (UPCI) Peptide Synthesis Facility
(Shared Resource). Peptides were 
 
 
 
90% pure based on HPLC
profile and MS/MS mass spectrometric analysis performed by the
UPCI Protein Sequencing Facility (Shared Resource).
 
Isolation of Patient and Normal Donor PBMC-Derived T Cells.
 
40–100 ml of patient or normal donor heparinized blood was ob-
tained with informed consent under IRB-approved protocols and
diluted 1:2 with HBSS, applied to ficoll-hypaque gradients (LSM;
Organon-Teknika) per the manufacturer’s instructions, and cen-
trifuged at 550 
 
g
 
 for 25 min at room temperature. Patient and
normal donor information is provided in Table I. PBMCs at the
buoyant interface were recovered and washed twice with HBSS
to remove residual platelets and ficoll-hypaque. HLA-DR4
 
 
 
 sta-
tus was confirmed by flow cytometry using the anti-HLA-DR4 
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Table I.
 
HLA-DRB1
 
*
 
0401-positive Patients Evaluated in this Study
 
 
 
-MAGE response
Patient Age Sex Stage Treatment
Disease status
at time of
evaluation (y)
RT-PCR
MAGE-6 (
 
 
 
/
 
 
 
) 121 140 246
Melanoma (
 
n
 
 
 
 
 
 18)
SLM1 71 F IV S, DC/peptide NED (1.5)
 
 
 
Th1 Th1 Th1
SLM2 64 F IV S, IFN-
 
 
 
NED (5.0)
 
 
 
Th1 Th1 Th1
SLM5 34 M IV S, IFN-
 
 
 
NED (4.1) NA Th1 Th1
 
 
 
SLM6 37 F I S, IFN-
 
 
 
NED (1.9) NA Th1 Th1 Th1
SLM9 35 F III S, C, R NED (0.3)
 
 
 
Th1
 
  
 
SLM10 74 M IV S NED (0.4) NA Th1
 
  
 
SLM12
 
a
 
39 F IV S, C, IFN-
 
 
 
Stable
 
 
 
Th2 Th2 Th2
SLM14 52 M IV C Mets, brain
 
 
 
Th2 Th2 Th2
SLM16 64 M IV None Mets, liver/lung
 
    
 
Th2
SLM17 74 M IV S Mets
 
 
 
Th2 Th2 Th2
SLM18 31 F IV S, IFN-
 
 
 
Mets, brain
 
 
 
Th2 Th2 Th2
SLM19 56 M IV S, IFN-
 
 
 
, C Mets
 
  
 
Th2 Th2
SLM21 45 M IV S, IFN-
 
 
 
Mets
 
      
 
SLM22 57 F IV S Mets
 
 
 
Th2 Th2 Th2
SLM23 63 M I S, IFN-
 
 
 
NED (1.2)
 
 
 
Th2 Th1/2
 
 
 
SLM24 36 F IV S Mets
 
 
 
Th2 Th2 Th2
SLM25 42 M IV S Mets
 
  
 
Th2  
SLM26 41 F IV S Mets       
RCC (n   18)
SLR2 51 F IV S NED (0.3)   Th1 Th1 Th1
SLR3 45 M IV S Mets NA   Th2  
SLR4 49 F IV S, IL-2 Mets NA Th2 Th2 Th2
SLR5 79 M IV S, IFN-  Mets NA Th2 Th1/2 Th2
SLR6 64 M I S NED (0.3) NA Th1 Th1 Th1
SLR7 52 F I S Local Dis. NA   Th2
SLR8 49 M IV C, R Mets NA   Th2  
SLR9 53 F I S NED (0.1) NA Th1   
SLR10 41 M IV S, C, R Mets NA Th2   
SLR11 58 M IV S, IFN- , R Mets       
SLR12 58 M I S Local Dis. NA   Th2
SLR13 71 M I S Local Dis. NA     
SLR14 75 F I S Local Dis. NA   Th2  
SLR15 58 M I S NED (0.1) NA Th1   
SLR16 57 M IV S, R Mets      Th2
SLR17 53 M II S Local Dis. NA   Th2
SLR18 62 F II S Local Dis. NA Th2 Th2 Th2
SLR19 67 M IV S, IFN- , R Mets NA Th2 Th2 Th2
AIT, adoptive immunotherapy (VDLN cells); C, chemotherapy; Mets, metastatic disease; R, radiotherapy; S, surgery; DC/peptide, dendritic cell plus
synthetic melanoma peptide vaccine; IFN- , IFN-  therapy; NED, no evidence of disease at time of blood draw; NA, not available for evaluation.
aPatient with ocular melanoma. Th1 or Th2 assignment for peptide reactivity reflects donor responses of  10 spots/50,000 CD41 T cells as deter-
mined in IFN-  or IL-5 ELISPOT assays, respectively.622 MAGE-6 Reactive Th1-/Th2-type CD4  T Cell Responses
reactive mAb clone 359–13F10 (IgG; provided by Dr. Janice
Blum, Indiana University School of Medicine, Indianapolis, IN)
in indirect immunofluorescence assays. PBMCs were diluted to
107/ml in AIM-V medium (GIBCO BRL) and incubated for 60
min at 37 C in T75 vented flasks (COSTAR), with subsequently
harvested adherent cells used to generate DCs (see below) and
nonadherent cells frozen in 90% FCS containing 10% DMSO
(Sigma-Aldrich) at 107 lymphocytes/vial using controlled-rate
freezing technique. On the day of establishing DC–T cell cul-
tures, nonadherent cells were thawed and washed twice with
HBSS. CD4  T cells were then isolated using MACS™ (Mil-
tenyi Biotec) anti–human CD4 beads and MiniMACS™ col-
umns per the manufacturer’s protocol. CD4  T cell yields were
typically 25–35% of starting PBMC numbers loaded, with purity
exceeding 97% as assessed by flow cytometry.
Induction of Antitumor T Effector Lymphocytes. Autologous
DCs were prepared as described previously in 7-d cultures of
plastic-adherent PBMCs in AIM-V media supplemented with
rhGM-CSF and rhIL-4 (26). Harvested, nonadherent DC (2  
105) were then cocultured with 2   106 autologous CD4  T cells
in the presence of 10  M synthetic peptides for 7 d in RPMI-
1640 containing 10% FBS and no exogenously added cytokines.
Responder T cells were then harvested and analyzed for MAGE-6
peptide specificity in ELISPOT assays.
IFN-  and IL-5 ELISPOT Assays for Peptide-Reactive CD4  T
Cell Responses. To evaluate the frequencies of peripheral blood
CD4  T cells recognizing peptide epitopes, ELISPOT assays for
IFN-  and IL-5 were performed as described previously (26, 27,
37). Briefly, CD4  T cell responses were evaluated by both IFN- 
(Th1) and IL-5 (Th2) ELISPOT assays. For ELISPOT assays,
96-well multiscreen hemagglutinin antigen plates (Millipore)
were coated with 10  g/ml of anti–human IFN-  mAb (1-D1K;
Mabtech) or 5  g/ml of anti–human IL-5 (BD Biosciences) in
PBS (GIBCO BRL/Life Technologies) overnight at 4 C. Un-
bound antibody was removed by four successive washing with
PBS. After blocking the plates with RPMI1640/10% human se-
rum (1 h at 37 C), 105 CD4  T cells and T2.DR4 cells (2   104
cells) were seeded in multiscreen hemagglutinin antigen plates.
Synthetic peptides (stocks at 1 mg/ml PBS) were then added to
appropriate wells at a final concentration of 10  g/ml. Negative
peptide control wells contained CD4  T cells with T2.DR4 cells
pulsed with Malaria-CS326–345 peptide, with T2.DR4 cells alone
serving as the APC control. Positive controls were T cells plated
in the presence of 5  g/ml PHA (Sigma-Aldrich). Culture me-
dium was AIM-V (GIBCO BRL/Life Technologies) at a final
volume of 200  l/well. Plates were incubated at 37 C in 5%
CO2 for 24 h in the case of IFN-  ELISPOT assays and for 40 h
in IL-5 ELISPOT assays. After incubation, supernatants of cul-
ture wells were harvested for ELISA analysis, and plates washed
with PBS/0.05% Tween 20 (PBS/T) to remove cells. Captured
cytokine was detected at sites of its secretion by incubation for
2 h with biotinylated mAb anti–human IFN-  (7-B6–1; Mabtech)
at 2  g/ml in PBS/0.5% BSA or biotinylated mAb anti–human
IL-5 (BD Biosciences) at 2  g/ml in PBS/0.5% BSA. Plates were
then washed six times with PBS/T, and avidin-peroxidase com-
plex (diluted 1:100; Vectastain Elite Kit; Vector Laboratories) was
added for 1 h. Unbound complex was removed by three succes-
sive washings with PBS/T and three rinses with PBS alone. AEC
substrate (Sigma-Aldrich) was added and incubated for 5 min for
the IFN-  ELISPOT assay and the TMB substrate for peroxidase
(Vector Laboratories) was added and incubated for 10 min for the
IL-5 ELISPOT assay. All determinations were performed in trip-
licates, with spots imaged using the Zeiss AutoImager (and statis-
tical comparisons determined using a Student two-tailed t test
analysis). The data are represented as mean IFN-  or IL-5 spots
per 100,000 CD4  T cells analyzed.
TGF- 1 and IL-10 ELISAs. Supernatants were harvested
from ELISPOT plates at the endpoint of the culture period and
pooled for a single stimulus (i.e., a given peptide, etc.) and frozen
at –20 C until analysis by cytokine-specific ELISA. Cytokine
capture and detection antibodies and recombinant cytokine were
purchased from BD Biosciences and used in ELISA assays per the
manufacturer’s instructions. The lower limit of detection for the
TGF-  assay was 60 pg/ml, while that of the IL-10 ELISA was 7
pg/ml. In the case of IL-10, 1–5 responder CD4  T cells spots
imaged in an IL-10 ELISPOT equated with  12–17 pg/ml IL-
10 as determined in the IL-10 ELISA assay (unpublished data).
PCR Analysis. PCR analyses were performed to determine
patient HLA-DR4 genotype using a commercial PCR panel ac-
cording to the manufacturer’s instructions (Dynal) and PBL. RT-
PCR analysis was also used to determine tumor expression of
MAGE-6 mRNA. The following primer set was used: MAGE-6
(forward: TGGAGGACCAGAGGCCCCC, reverse: CAG-
GATGATTATCAGGAAGCCTGT, product size 728 bp with
cycles: melting 94 C for 1 min, annealing 68 C for 1 min, exten-
sion 72 C for 1 min).
Results
Normal HLA-DR 1*0401  Donors Fail to React or Dis-
play a Mixed Th1/Th2 CD4  Response to MAGE-6 Epitopes
after Primary In Vitro Stimulation.  MAGE-6 peptides were
not recognized by freshly-isolated CD4  T cells harvested
from normal HLA-DRB1*0401  donors (unpublished
data). To determine if CD4  precursors were present in
normal donors and to identify the balance of Th1-type ver-
sus Th2-type responses, we implemented IFN-  and IL-5
ELISPOT assays, respectively. Although both IL-4 and IL-5
have been previously reported as signature cytokines for
Th2-type T cell responses (38, 39), we chose the IL-5 assay
over the IL-4 ELISPOT assay to screen for Th2-type
CD4  T cell reactivity for technical reasons, mainly the
much lower backgrounds and higher signal-to-noise ratio
observed for the IL-5 ELISPOT system (37, 40).
To evaluate whether normal donors could be prompted
to recognize any of these sequences, isolated CD4  T cells
derived from the PBMCs of HLA-DR4  normal do-
nors were stimulated with autologous immature DCs in
the presence of the individual MAGE-6 peptides (i.e.,
MAGE-6121–144, MAGE-6140–170, or MAGE-6246–263). We
chose this in vitro stimulation (IVS) protocol since the
DCs generated were poor IL-12 producers upon CD40 li-
gation and these antigen presenting cells do not appear to
skew CD4  T cell responses in either a Th1-type or Th2-
type manner (unpublished data). Hence, we consider these
as “neutral” DC for CD4  T cell stimulations. 1 wk after
stimulation, CD4  T cells were used as responders against
T2.DR4 target cells pulsed with the candidate DR4-bind-
ing peptides. As shown in Fig. 1, an analysis of 10 normal
HLA-DR4  donors revealed either very low responsive-
ness or responses that were equivocal with regard to their
balance of IFN-  versus IL-5 spot production. Although623 Tatsumi et al.
we did not perform these analyses in a manner that al-
lowed for an assessment of coordinate cytokine production
from a given CD4  T cell, we considered these results
from normal donors to reflect Th0-type or mixed Th1-
type/Th2-type responses.
Th1-type versus Th2-type Immunoreactivity of CD4  T
Cells Against HLA-DR4-Presented MAGE-6 Epitopes in
HLA-DR4  RCC or Melanoma Patients.  Recent reports
have suggested that CD4  T cells infiltrating progressor
RCC and melanoma may display a predominant Th2-bias
in response to TCR ligation (41, 42). We used the IFN- 
(Th1-type) and IL-5 (Th2-type) ELISPOT assays to dis-
cern whether such a bias existed in the peripheral blood
CD4  T cell repertoire of HLA-DR 1*0401  patients
with RCC or melanoma using the identical IVS system
outlined above for normal donors.
Overall, the peripheral blood CD4  T cell responses
were evaluated from 18 RCC and 18 melanoma patients
(Table I). Among these patients, 4/18 RCC patients and
7/18 melanoma patients were disease-free (i.e., no-evi-
dence of disease [NED]) at the time of analysis, with all
other patients presenting with active disease. As shown in
Fig. 2, patients with active disease (either RCC or mela-
noma) displayed strongly Th2-polarized CD4  T cell re-
sponses, whereas patients that were disease-free at the time
of analysis were strongly Th1-polarized in their reactivity
to the three MAGE-6 epitopes evaluated. Not every pa-
tient reacted against each of the peptides tested, but if they
did respond to a given epitope, this response was strongly
polarized in accordance with the disease status of the indi-
vidual (i.e., Th2 if active disease, etc., Table I). Whereas
the melanoma patients were all essentially diagnosed with
Figure 1. Analysis of the Th1-
type vs. Th2-type CD4  T cell
response to MAGE-6 peptides in
HLA-DR 1*0401  normal do-
nors. Peripheral blood CD4  T
cells were isolated from normal
donors and stimulated with au-
tologous, “immature” DCs in the
presence of the MAGE-6121–144
(M121), MAGE-6140–170 (140L)
(M140), or MAGE-6246–263
(M246) peptides for 7 d, in the
absence of exogenous cytokines.
Responder CD4  T cells were
then analyzed for their reactivity
to T2.DR4 cells pulsed with in-
dividual MAGE-6 peptides in
both IFN-  and IL-5 ELISPOT
assays. Each symbol within a
panel represents the combined
IFN- /IL-5 ELISPOT data for
an individual normal donor.
Figure 2. Analysis of the Th1-type vs. Th2-
type CD4  T cell response to MAGE-6 peptides
in HLA-DR 1*0401  patients with RCC or
melanoma. Peripheral blood CD4  T cells were
isolated from patients with RCC or melanoma
and stimulated for 7 d with autologous “imma-
ture” plus MAGE-6 peptides as described in the
legend to Fig. 1. Responder CD4  T cells were
then analyzed for their reactivity to T2.DR4 cells
pulsed with individual MAGE-6 peptides in both
IFN-  and IL-5 ELISPOT assays. Each symbol
within a panel represents the combined IFN- /
IL-5 ELISPOT data for an individual patient,
with filled circles indicating patients with active
disease and open inverted triangles reflecting pa-
tients that were free of disease at the time of eval-
uation, as described in Table I.624 MAGE-6 Reactive Th1-/Th2-type CD4  T Cell Responses
stage IV disease (with the exception of patients SLM6,
SLM9, and SLM23), the RCC patients were approxi-
mately equally represented by individuals with stage I or
stage IV disease (with patient SLR17 exhibiting stage II
disease). A comparison of whether the observed Th2-
polarization in CD4  T cell response to MAGE-6 pep-
tides (Fig. 2, top series) was correlated with disease stage in
RCC patients, provided no statistically significant associa-
tions (stage I versus stage IV for MAGE-6121–144 [P  
0.89]; for MAGE140–170 [P   0.27]; for MAGE-6246–263
[P   0.50]).
Patients with active disease were not predisposed to a
general Th2-type polarization in their CD4  T cell re-
sponses. An evaluation of CD4  T cells from the patients
with melanoma or RCC, or normal donors revealed mixed
Th1-/Th2-type responses to PHA mitogenic stimulation
in IFN-  and IL-5 ELISPOT assays (Fig. 3). As groups, pa-
tients with active disease, patients with no evidence of dis-
ease and normal donors proved indistinguishable in their
bulk CD4  T cell responses to mitogen. Using a series of
newly defined HLA-DR4–presented helper epitopes de-
fined from the influenza virus matrix protein (FluM160–73;
reference 35) and EBV EBNA-1 (EBNA-1519–533; reference
36), we were able to evaluate CD4  T cell responses in pa-
tients SLR18 and SLR19 who each presented with active
disease at the time of analysis (Fig. 4). In each case, strongly
Th2-type biased CD4  T cell reactivity was noted against
the three MAGE-6 epitopes, with concurrent Th1-type
polarized CD4  T cell antiviral responses.
Patients with RCC or Melanoma Do Not Exhibit Th3-/Tr-
type CD4  T Cell Responses to MAGE-6 Epitopes. Al-
though no ELISPOT is currently available to evaluate
TGF-  production, an index for the bioactivity of the Tr-
type CD4  T cells, we analyzed the supernatant from the
peptide-stimulated ELISPOT wells for TGF-  levels using
a cytokine specific ELISA assay. All supernatants were be-
low the level of detection for secreted TGF-  (i.e.,  60
pg/ml, unpublished data). We also evaluated these superna-
tants for the presence of IL-10 production and were unable
to demonstrated peptide-specific secretion of this cytokine
(i.e.,  7 pg/ml, unpublished data). Based on direct com-
parison to a newly developed IL-10 ELISPOT assay, as few
as 1–5 IL-10 secreting CD4  T cells (per 50,000) would
have registered as 12–17 pg IL-10/ml in our ELISA assay
(unpublished data). Hence we believe that these patients
have, at best, very few (frequencies  1/50,000 CD4  T
cells) in their peripheral blood.
Successful therapy associated with NED status is linked
to a conversion of peripheral Th2-type to Th1-type CD4 
T cell response to MAGE-6 epitopes. RCC patient SLR12
with stage I disease was surgically managed, resulting in dis-
ease-free status. Peripheral blood CD4  T cell responses
were evaluated pre- and postsurgery in IFN-  and IL-5
ELISPOT assays against the MAGE-6121–144, MAGE-
Figure 3. Patient CD4  T cells from
IVS cultures exhibit normal, mixed
Th1/Th2 responses to PHA mitogenic
stimulation regardless of disease status.
CD4  T cell cultures obtained from IVS
outlined in Figs. 1 and 2 were analyzed
for their response to PHA mitogen (5
 g/ml). Each symbol represents the
combined IFN- /IL-5 ELISPOT data
for an individual, with melanoma or
RCC patients with active disease de-
noted by filled circles, and patients with
no evidence of disease indicated by
open circles.
Figure 4. Peripheral blood CD4  T cells from patients
SLM18 and SLM19 display Th2-type reactivity to
MAGE-6 epitopes, but Th1-type reactivity to viral
epitopes. CD4  T cells were stimulated with immature
autologous DCs pulsed with the indicated peptides for 1
wk, as outlined in Figs. 1 and 2. Responder CD4  T cells
were then analyzed for their reactivity to T2.DR4 cells
pulsed with individual MAGE-6, influenza matrix, or
EBV peptides in both IFN-  and IL-5 ELISPOT assays.625 Tatsumi et al.
6140–170, and MAGE-6246–263 epitopes, as outlined above.
Weak Th2-biased responses were noted against the MAGE-
6121–144 and MAGE-6246–263 peptides before surgery, while
weak, but Th1-biased responses against these epitopes were
noted 1 mo postsurgery (Fig. 5 A).
Patient SLM1 with stage IV melanoma was treated with
an autologous DC-based vaccine (UPCI 95–060) and
achieved a complete response in March 1997. Peripheral
blood CD4  T cells were isolated both pre- (8/96 and 3/97)
and post- (4/97, 11/98) regression of disease. Patient SLM1
was disease-free at the time of both postregression time
points. As shown in Fig. 5 B, this patient reacted to all
three MAGE-6 epitopes in a strongly Th2-biased manner
before regression, but displayed only Th1-type reactivity
after the tumor burden was clinically eradicated.
Discussion
We analyzed peripheral blood T cells harvested from
HLA-DR 1*0401  normal donors and patients with
RCC or melanoma for the magnitude and nature of CD4 
T cell responses to 3 MAGE-6 epitopes that we have re-
cently identified as HLA-DR 1*0401-presented epitopes
(unpublished data). We observed a dominance of Th2-type
(and a frequent lack of any Th1-type) CD4  T cell re-
sponses to these MAGE-6 epitopes in RCC and melanoma
patients with active disease (Fig. 2). In marked contrast,
normal donors and patients that had been successfully
treated and were disease free at the time of analysis, dis-
played either mixed Th1-/Th2-type or strongly Th1-
polarized immunity to these same peptides. It should be
stressed that these polarized CD4  T cell responses are spe-
cific for the tumor peptides tested and do not reflect the
general tendency of the donor to respond in a generically
Th2- (or Th1-) biased fashion, as the mitogen (PHA) con-
trol spot frequencies obtained for both the IL-5 and IFN- 
ELISPOT assays were indiscriminant between patients
with cancer, patients that were free of disease, and normal
donors (Fig. 3). In addition, for two RCC patients (SLR18
and SLR19) evaluated, Th2-type immunity to MAGE-6
peptides coexisted with strong Th1-type immunity to in-
fluenza- and EBV-derived helper epitopes (Fig. 4). Overall,
although these data derive from relatively few patients, they
suggest that Th2-type dominated CD4  T cell responses
against MAGE-6 epitopes may correlate with active disease
status in the patient.
However, when the results of RCC patients with stage I
disease were compared with those of RCC patients with
stage IV disease, we were unable to determine any signifi-
cant linkage between the degree of Th2-polarization to
MAGE-6 epitopes and disease-stage in patients with active
disease. As MAGE-6 appears to represent an early tumor-
associated antigen, observed in even premalignant lesions
(29–31), our results may suggest that skewing of a normally
mixed Th1-/Th2-type MAGE-6-specific CD4  T cell re-
sponses toward Th2-dominated immunity may also be an
early event in disease progression. Such polarization could
result from chronic antigenic restimulation in situ through-
out disease ontogeny, and could be initiated even in indi-
viduals with premalignant MAGE-6  lesions, potentially
serving as a facilitator of disease progression.
Clearly, far more extensive longitudinal studies will be
required to determine the prognostic significance of differ-
ential Th1- versus Th2-type in the progression, clearance,
and/or recurrence of disease. Although we are now in the
process of initiating these types of comprehensive studies at
the UPMC and UPCI, our preliminary data provided in
Fig. 5, suggests that in an RCC patient that was surgically
managed and a melanoma patient that was treated with an
autologous DC-based vaccine, that Th2-biased responses
Figure 5. Analysis of the Th1-type vs.
Th2-type CD4  T cell response to MAGE-6
peptides in HLA-DR 1*0401  RCC and
melanoma patients pre/posttherapy. Periph-
eral blood T cells were isolated from an RCC
patient SLR12 (A) and melanoma patient
SLM1 (B) pre- or posttherapy. In both cases,
therapy resulted in disease-free status. In the
case of patient SLR12, blood was drawn at
the time of surgery (filled circle) and 2 mo
postsurgery (open inverted triangle). Patient
SLM1 was treated with a DC-based vaccine,
resulting in a complete response in 3/97.
Blood was drawn pretherapy and during ther-
apy, but before regression (filled circles) and
after complete regression (open inverted tri-
angles). 7-d IVS were performed as outlined
in Fig. 1, with responder CD4  T cells ana-
lyzed for their reactivity to T2.DR4 cells
pulsed with individual MAGE-6 peptides in
both IFN-  and IL-5 ELISPOT assays.626 MAGE-6 Reactive Th1-/Th2-type CD4  T Cell Responses
to MAGE-6 epitopes shifted to Th1-biased response after
the patient achieved disease-free status. Furthermore,
based on preliminary MHC-peptide tetramer analysis,
MAGE-6 reactive CD4  T cells were observed to increase
in the peripheral blood, at least transiently, as soon as 1–2
mo after successful therapy (unpublished data), which may
support the register of these helper T cell responses with
clinical benefit.
An additional important consideration in our prospective
analyses will be a careful comparison of systemic versus tu-
mor-associated CD4  T cell response polarization to
MAGE-6 epitopes. It would be hypothesized that the most
dramatic polarizations and highest frequencies of non-Th1
polarized tumor antigen-specific CD4  T cells would be
identified in the tumor microenvironment and tumor-
draining lymph nodes. Although we have reported an es-
sentially qualitative Th2-type bias in response to MAGE-6
peptides in the peripheral blood of patients with active dis-
ease, we have been thus far, unable to demonstrate systemic
antigen-specific Th3/Tr-type CD4  T cell responses to
these epitopes. This may suggest that these latter responses
are rare-events in the patient, or alternatively, that they
may be concentrated and best observed within the tumor-
involved tissues of the patient.
An analysis of the data presented in Table I indicates that
12/15 (i.e., 80%) evaluable melanoma biopsies expressed
the MAGE-6 antigen as deduced by RT-PCR analysis. In
all 12 of these MAGE-6  patients, Th1-type or Th2-type
CD4  T cell responses were detected by ELISPOT analysis
against at least one of the three MAGE-6 epitopes analyzed
in this study. In 2/3 cases where the patient’s tumor failed
to express the MAGE-6 gene product, the patient’s CD4 
T cells did not react to MAGE-6 epitopes. The resected
tumor in patient SLM22, however, failed to express the
MAGE-6 mRNA, yet Th2-type CD4  T cell responses
were observed against all three MAGE-6–derived helper
epitopes. This result may be due to MAGE-6 expression by
nonresected metastatic lesions in this stage IV patient with
active disease. Alternatively, the anti-MAGE-6 CD4  T
cells may be reacting or cross-reacting against homologous
epitopes derived from other MAGE-A family member pro-
teins. An analysis of all MAGE-A family members suggests
that this possibility would be most likely for the MAGE-
6121–144 peptide, which is identical to the homologous
MAGE-3 sequence, but which differs in sequence at 3 or
more key positions with all other MAGE-A members (un-
published data). This possibility is less likely for the
MAGE-6140–170 and MAGE-6246–263 epitopes that differ
from the homologous MAGE-3 sequence by two noncon-
servative D156S and Y249H substitutions within the puta-
tive core binding epitope (unpublished data). Additional
nonconservative changes in these two epitope sequences
are noted when comparing MAGE-6 to all other MAGE-A
members. As corollary analyses, we will prospectively de-
termine whether patient CD4  T cells isolated using spe-
cific HLA-DR4/MAGE-6 peptide tetramers recognize the
homologous MAGE-A family sequences.
In these studies, we chose an in vitro induction assay us-
ing autologous immature monocyte-derived (i.e., myeloid)
DCs that appeared not to skew the nature of the isolated
CD4  T cell response to a given epitope. In preliminary
studies, we analyzed freshly-isolated CD4  T cells from
melanoma patients as the responders (arguably recall
responses) to peptide-pulsed T2.DR4 targets in our
ELISPOT assays and discerned the same cytokine (IFN
versus IL-5) secretion bias, as we report after IVS. We sys-
tematically implemented the 7-d IVS (using immature my-
eloid DCs) protocol as this amplified the technically-
detectable (ZEISS AutoImager) spot numbers in each of
the assays, without changing the bias of cytokines pro-
duced. We feel that this is a reasonable amplification tool in
the outlined work. As this report was designed to reflect, as
closely as possible, the in situ peripheral repertoire, we have
not attempted to delineate how other DC subsets or condi-
tioning regimens alters the bias of the responder repertoire
in the current manuscript. Our data, however, may suggest
that immature DCs, such as have been implemented in a
number of vaccine trials (43, 44), may be clinically-inferior
to strong DC1-type cells (producing high quantities of IL-
12; references 45 and 46) due to their comparative inability
to promote strong Th1-biased immunity in the face of ex-
isting Th2-type responses.
So, why does the tumor-reactive CD4  T cell reper-
toire shift to a Th2-dominated phenotype in situ in cancer
bearing patients? A number of nonmutually exclusive hy-
potheses have been proffered. These include: immune de-
viation via chronic antigenic stimulation and selective sen-
sitivity of Th1-type CD4  T cells to activation-induced
apoptosis (47), the promotion of DC2-type (i.e., Th2-type
promoting) antigen-presenting cell function conditioned
by tumor-secreted cytokines and chemokines (i.e., IL-10,
TGF- , SDF-1; references 48 and 49), and the enforced
repolarization of Th1 type-responses into Th2-type re-
sponses in situ (50), among others. Using MHC/MAGE-6
peptide tetramers, we anticipate the ability to assess the
proapoptotic phenotype of specific CD4  T cells in pa-
tients with active disease versus those that have achieved
NED status in future studies. Our current studies investi-
gating CD4  T cell response to viral epitopes suggest that
patient DCs do not exert a dominant DC2 functional phe-
notype in vitro. Clearly these important issues demand in-
tense prospective evaluation.
Although we are currently analyzing DC-based vaccines
that are capable of repolarizing Th2-type tumor-reactive
CD4  T cells toward Th1-type immunity, this may not
necessarily represent the clinically preferred modality for
the treatment of existing disease. As previously mentioned,
Th2-type tumor-specific CD4  T cells may well prove
productive collaborators to Th1-type CD4  T cells in me-
diating tumor regression via different, but complementary
mechanisms (9–12, 14, 20). This may be particularly im-
portant in the case of MHC class I–loss variant tumors that
will be impervious to Th1-type CD4  T cell-sponsored
cytotoxicity mediated by CD8  antitumor T cells (10, 11).
Regardless of which underlying mechanism leads to tumor
regression, it appears clear that strong Th1-type tumor-spe-627 Tatsumi et al.
cific T cell responses will be important in the maintenance
of durable cellular immunity (12) and extended disease-free
intervals in those patients at high-risk for recurrence.
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